BC Extra | Jul 26, 2018
Company News

Reese succeeding Harper as Amgen EVP of R&D

Amgen Inc. (NASDAQ:AMGN) said EVP of R&D Sean Harper will retire and be succeeded by SVP of Translational Sciences and Oncology David Reese. The company also reported 2Q18 earnings on Thursday after market hours that...
BC Week In Review | Jul 7, 2017
Clinical News

Daiichi ends Japanese development of Coherus' Enbrel biosimilar

Daiichi Sankyo Co. Ltd. (Tokyo:4568) discontinued development in Japan of CHS-0214 (BAX 2200), a biosimilar of Enbrel etanercept from Amgen Inc. (NASDAQ:AMGN), to treat rheumatoid arthritis. Coherus BioSciences Inc. (NASDAQ:CHRS) said it regained territorial rights...
BC Extra | Jul 5, 2017
Company News

Daiichi ends development of Coherus' biosimilar of Enbrel

Coherus Biosciences Inc. (NASDAQ:CHRS) slipped $0.25 to $14.40 on Wednesday after partner Daiichi Sankyo Co. Ltd. (Tokyo:4568) discontinued development in Japan of CHS-0214 , a biosimilar of Enbrel etanercept from Amgen Inc. (NASDAQ:AMGN), to treat rheumatoid...
BC Week In Review | Apr 14, 2017
Company News

Inovalon, Amgen deal

Inovalon's Avalere Health unit will use its data and analytics to support development of outcomes-based contracts for Amgen’s rheumatoid arthritis products. Amgen markets RA drug Enbrel etanercept, a recombinant p75 tumor necrosis factor (TNF) receptor...
BC Week In Review | Dec 21, 2016
Clinical News

Lifmior regulatory update

EMA’s CHMP recommended approval of Pfizer’s Lifmior etanercept, a product identical to Enbrel , to treat rheumatoid arthritis (RA), juvenile idiopathic arthritis, psoriatic arthritis, axial spondyloarthritis, plaque psoriasis and pediatric plaque psoriasis. Pfizer has rights to...
BC Extra | Dec 16, 2016
Company News

Celltrion biosimilar among CHMP recommendations

EMA’s CHMP recommended approval of a basket of candidates on Friday, including biologics from Pfizer Inc. (NYSE:PFE) and Celltrion Inc. (KOSDAQ:068270). CHMP recommended Pfizer’s Lifmior etanercept, a product identical to Enbrel , to treat rheumatoid arthritis,...
BC Week In Review | Jan 18, 2016
Clinical News

CHS-0214: Phase III data

The 52-week, double-blind, international Phase III RApsody (CHS-0214-02) trial in about 620 patients with moderate to severe RA showed that once-weekly 50 mg subcutaneous CHS-0214 met the primary endpoint of demonstrating equivalence to 50 mg...
BC Week In Review | Nov 16, 2015
Clinical News

CHS-0214: Phase III data

The double-blind, international Phase III RaPsOdy (CHS-0214-04) trial in about 496 patients with moderate to severe chronic plaque psoriasis who are naive to systemic biologic therapy showed that 50 mg subcutaneous CHS-0214 met the co-primary...
BC Week In Review | Jun 1, 2015
Clinical News

CHS-0214: Completed Phase III enrollment

Coherus completed enrollment in the double-blind, international Phase III RApsody (CHS-0214-02) trial comparing 50 mg subcutaneous CHS-0214 once weekly vs. 50 mg Enbrel etanercept once weekly for 24 weeks in about 620 patients. The completion...
BC Week In Review | Jun 1, 2015
Clinical News

CHS-0214: Completed Phase III enrollment

Coherus completed enrollment in the double-blind, international Phase III RaPsOdy (CHS-0214-04) trial comparing 50 mg subcutaneous CHS-0214 vs. 50 mg Enbrel etanercept in about 496 patients. The completion of enrollment in CHS-0214-04 and the Phase...
Items per page:
1 - 10 of 47